Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert K. who wrote (8081)	12/16/1998 4:04:00 PM
From: aknahow	Respond to of 17367

Bob, something got lost in translation. <g>

To: Robert K. who wrote (8081)	12/17/1998 9:07:00 PM
From: aknahow	Read Replies (2) \| Respond to of 17367

Interesting post on Lyme disease at Yahoo. Mentioned lymenet.org and neuropathy.org. BTW there are seven XOMA patents that include Lyme disease in the text. Yes, I understand that patents are one thing and a cure is another but the patents hold out some hope that something can be done. 5837678 Borrelia burgdorferi is the pathogen responsible for Lyme Disease and associated arthritis and it possesses an LPS-like complex on its cell walls which is different from but structurally related to that of E. coli. The effect of administration of BPI protein products on inhibition of Borrelia burgdorferi LPS in a Limulus Amoebocyte Lysate (LAL) inhibition assay was determined. Specifically, an LAL assay according to the method of Example 15 was conducted measuring the effect of rBPI.sub.23 on Borrelia burgdorferi LPS administered at 2.5 .mu.g/mL and E. coli 0113 LPS administered at 2 ng/mL. The results depicted in FIG. 10 show that rBPI.sub.23 neutralizes the effects of both Borrelia burgdorferi LPS and E. coli 0113 LPS in the LAL assay.